Literature DB >> 18204965

Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.

Xiao-Jun Huang1, Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, Yu-Hong Chen, Yu Wang, Wei Han, Huan Chen.   

Abstract

We evaluated the safety and efficacy of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor priming and short-term immunosuppressive agents for prophylaxis of relapse in patients with advanced leukemia after human leukocyte antigen (HLA)-mismatched T cell-replete hematopoietic stem cell transplantation (HCT). Twenty-nine patients received prophylactic DLI at a median 75 (33-120) days after HCT. Acute graft-vs-host disease (GVHD) grades 3-4 occurred in six patients, and all cases were controlled. Eleven patients were alive and relapse-free with a probability of leukemia-free survival (LFS) of 37.3 +/- 9.6% at 3 years. Chronic GVHD was associated with a lower relapse rate and higher probability of LFS. Prophylactic-modified DLI is feasible in patients with advanced leukemia to prevent relapse after HLA-mismatched HCT.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18204965     DOI： 10.1007/s10875-007-9166-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  25 in total

Review 1.  Who should be transplanted for AML?

Authors:  F R Appelbaum
Journal:  Leukemia       Date:  2001-04       Impact factor: 11.528

2.  [Standardization and Quality Control in Flow Cytometric Enumeration of CD34(+) cells]

Authors:  Yanrong Liu; Shanshan Chen; Hong Yu
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2000-12

3.  Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.

Authors:  E P Alessandrino; P Bernasconi; D Caldera; A Colombo; L Malcovati; G Martinelli; M Bonfichi; G Pagnucco; L Salvaneschi; C Bernasconi
Journal:  Bone Marrow Transplant       Date:  1999-03       Impact factor: 5.483

4.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.

Authors:  X-J Huang; D-H Liu; K-Y Liu; L-P Xu; H Chen; W Han; Y-H Chen; J-Z Wang; Z-Y Gao; Y-C Zhang; Q Jiang; H-X Shi; D-P Lu
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

5.  Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia.

Authors:  X-J Huang; D-H Liu; L-P Xu; H Chen; W Han; K-Y Liu; D-P Lu
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

6.  Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.

Authors:  Sang-Kyun Sohn; Jin-Tae Jung; Dong-Hwan Kim; Nan-Young Lee; Kwang-Woon Seo; Yee-Soo Chae; Soung-Won Park; Jong-Gwang Kim; Jang-Soo Suh; Kyu-Bo Lee
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

7.  Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han
Journal:  Haematologica       Date:  2007-03       Impact factor: 9.941

8.  Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions.

Authors:  Xiao-Jun Huang; Ying Jun Chang; Xiang Yu Zhao
Journal:  Transpl Immunol       Date:  2006-11-20       Impact factor: 1.708

9.  Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia.

Authors:  R A Clift; C D Buckner; F R Appelbaum; G Schoch; F B Petersen; W I Bensinger; J Sanders; K M Sullivan; R Storb; J Singer
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

10.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

Authors:  S Slavin; E Naparstek; A Nagler; A Ackerstein; S Samuel; J Kapelushnik; C Brautbar; R Or
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113
View more
  11 in total

Review 1.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

2.  Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study.

Authors:  Yu Wang; Xiang-Yu Zhao; Lan-Ping Xu; Xiao-Hui Zhang; Wei Han; Huan Chen; Feng-Rong Wang; Xiao-Dong Mo; Yuan-Yuan Zhang; Xiao-Su Zhao; Kong Y; Kai-Yan Liua; Xiao-Jun Huang; Xue-Zhong Yu; Ying-Jun Chang
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

3.  Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key.

Authors:  Haixia Fu; Lanping Xu; Daihong Liu; Xiaohui Zhang; Kaiyan Liu; Huan Chen; Yu Wang; Wei Han; Tingting Han; Xiaojun Huang
Journal:  Int J Hematol       Date:  2013-04-30       Impact factor: 2.490

4.  Hematopoietic stem cell transplantation in China: current status and prospects.

Authors:  Xiao-Jun Huang
Journal:  Am J Blood Res       Date:  2011-06-01

5.  Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome.

Authors:  X-D Mo; L-P Xu; X-H Zhang; D-H Liu; Y Wang; H Chen; C-H Yan; Y-H Chen; W Han; F-R Wang; J-Z Wang; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

6.  Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT.

Authors:  X-Y Qin; G-X Li; Y-Z Qin; Y Wang; F-R Wang; D-H Liu; L-P Xu; H Chen; W Han; J-Z Wang; X-H Zhang; J-L Li; L-D Li; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

Review 7.  HLA-haploidentical stem cell transplantation for hematologic malignancies.

Authors:  Ephraim J Fuchs; Xiao-jun Huang; Jeffrey S Miller
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-03       Impact factor: 5.742

Review 8.  Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.

Authors:  Meng Lv; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

Review 9.  Current status of haploidentical stem cell transplantation for leukemia.

Authors:  Xiao-jun Huang
Journal:  J Hematol Oncol       Date:  2008-12-31       Impact factor: 17.388

Review 10.  Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.

Authors:  Pier Edoardo Rovatti; Valentina Gambacorta; Francesca Lorentino; Fabio Ciceri; Luca Vago
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.